why choose us

First received: January 18, 2023

Clinical Trial: Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

Study Status: Completed

Recruit Status: RECRUITING

Condition: Advanced Endometrial Carcinoma

Study Type: INTERVENTIONAL


Official Title: A Phase 1 Study of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

Brief Summary: This phase I trial tests the safety, side effects, and best dose of combination therapy with pelcitoclax (APG-1252) and cobimetinib in treating patients with ovarian and endometrial cancers that have come back after a period of improvement (recurrent).APG-1252 is a drug that inhibits activity of proteins that prevent cell death, leading to increased cell death and reduced cell growth.Cobimetinib is used in patients whose cancer has a mutated (changed) form of a gene called BRAF.It is in a class of medications…

Read more